ArticleBMC infectious diseases2026
Evolution of resistance patterns in Enterobacterales according to urinary tract infection diagnosis: implications for empirical therapy in a French emergency department.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) caused by Enterobacterales are a major public health concern, with rising antimicrobial resistance (AMR) rates complicating empirical therapy. This study evaluated the evolution of resistance patterns in urinary Enterobacterales isolates from a French emergency department over an eight-year period (2013 vs. 2021-2022), focusing on implications for empirical treatment.
methodsA monocentric retrospective cohort analysis was conducted at the General Hospital of Melun, France. Urinary isolates from 2021 to 2022 were compared with 2013 baseline data. Resistance rates for cefotaxime, norfloxacin, trimethoprim-sulfamethoxazole (TMP/SMX), and fosfomycin were analyzed by species (Escherichia coli vs. other Enterobacterales) and clinical syndrome (e.g., pyelonephritis, cystitis). Statistical comparisons used chi-square or Fisher's exact tests.
resultsAmong 1,879 isolates (76% E. coli), resistance to cefotaxime (5.4%) and norfloxacin (8.7%) in E. coli significantly declined since 2013, while TMP/SMX resistance remained high (24.1%). Fosfomycin resistance was rare (1%). Resistance rates did not differ between colonizing and infecting strains. Complicated pyelonephritis isolates showed higher resistance (cefotaxime: 10%; norfloxacin: 12%) than uncomplicated cases, although these differences did not reach statistical significance.
conclusionLocal AMR trends support empirical use of cefotaxime or fluoroquinolones for pyelonephritis but discourage TMP/SMX. Fosfomycin remains first-line for cystitis. These findings underscore the need for localized surveillance to guide stewardship efforts. CLINICAL TRIALS: Not applicale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.